イサツキシマブ
参考資料

1 2  “Sarclisa Australian prescription medicine decision summary”. Therapeutic Goods Administration (TGA) (14 May 2020). 16 August 2020閲覧。
1 2 3 4 5 6  “Sarclisa EPAR”. European Medicines Agency (EMA) (24 March 2020). 25 June 2020閲覧。 Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑  “KEGG DRUG: イサツキシマブ”. www.kegg.jp. 2021年10月10日閲覧。
1 2 3 4 5 6  “Sarclisa- isatuximab injection, solution, concentrate”. DailyMed (2 March 2020). 26 March 2020閲覧。
↑  “再発性又は難治性多発性骨髄腫（RRMM）患者を対象にisatuximab（SAR650984）皮下投与又は静脈内投与とポマリドミド・デキサメタゾン投与を併用したときの薬物動態、安全性及び有効性を評価する多施設共同、非盲検、第Ib相試験｜関連する治験情報【臨床研究情報ポータルサイト】”. rctportal.niph.go.jp. 2021年10月10日閲覧。
↑  ImmunoGen, Inc. Announces Data Presentations at Upcoming 57th ASH Annual Meeting and Exposition
↑  “A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma”. Blood 126 (23):  509. (2015). doi:10.1182/blood.V126.23.509.509.
↑  “Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia”. ClinicalTrials.gov. 4 March 2020閲覧。
1 2  “FDA approves isatuximab-irfc for multiple myeloma”. U.S. Food and Drug Administration (FDA) (2 March 2020). 2 March 2020閲覧。  この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。
1 2  "FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma". U.S. Food and Drug Administration (FDA) (Press release). 2 March 2020. 2020年3月4日閲覧。  この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。
1 2 3 4 5 6 7 8  “Drug Trials Snapshots: Sarclisa”. U.S. Food and Drug Administration (FDA) (2 March 2020). 25 March 2020閲覧。  この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。
↑  “FDA approves isatuximab-irfc for multiple myeloma”. U.S. Food and Drug Administration (31 March 2021). 1 April 2021閲覧。
1 2 3  “サークリサ点滴静注100mg／サークリサ点滴静注500mg 添付文書”. www.info.pmda.go.jp. 2021年10月10日閲覧。
1 2  “Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma”. Blood Cancer Journal 9 (4):  41. (March 2019). doi:10.1038/s41408-019-0198-4. PMC 6440961. PMID 30926770. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440961/.
↑  “2020年5月28日 薬事・食品衛生審議会 医薬品第二部会 議事録”. www.mhlw.go.jp. 2021年10月10日閲覧。
1 2  “CD38: T Cell Immuno-Metabolic Modulator”. Cells 9 (7):  1716. (2020). doi:10.3390/cells9071716. PMC 7408359. PMID 32709019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408359/.
↑  “Role of CD38/cADPR signaling in obstructive pulmonary diseases”. Current Opinion in Pharmacology 51:  29–33. (2020). doi:10.1016/j.coph.2020.04.007. PMC 7529733. PMID 32480246. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529733/.
↑  “CD38 is the major enzyme responsible for synthesis of nicotinic acid-adenine dinucleotide phosphate in mammalian tissues”. The Biochemical Journal 362 (Pt 1):  125–30. (February 2002). doi:10.1042/0264-6021:3620125. PMC 1222368. PMID 11829748. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1222368/.
↑  “A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma”. Blood 129 (25):  3294–3303. (June 2017). doi:10.1182/blood-2016-09-740787. PMC 5482100. PMID 28483761. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482100/.
↑  “New investigational drugs with single-agent activity in multiple myeloma”. Blood Cancer Journal 6 (7):  e451. (July 2016). doi:10.1038/bcj.2016.53. PMC 5030378. PMID 27471867. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030378/.
↑  “Isatuximab”. Drugbank (May 20, 2019). 2021年10月10日閲覧。
↑  “CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma”. Frontiers in Immunology 9:  2722. (2018-11-28). doi:10.3389/fimmu.2018.02722. PMC 6279879. PMID 30546360. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279879/.
↑  “Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab”. Cells 8 (12):  1522. (2019). doi:10.3390/cells8121522. PMC 6953105. PMID 31779273. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953105/.
↑  Dhillon S (2020). “Isatuximab: First Approval”. Drugs 80 (9):  905–912. doi:10.1007/s40265-020-01311-1. PMID 32347476.
1 2  “Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab”. Cells 8 (12):  1522. (November 2019). doi:10.3390/cells8121522. PMC 6953105. PMID 31779273. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953105/.
↑  “Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab”. Cells 8 (12):  1522. (November 2019). doi:10.3390/cells8121522. PMC 6953105. PMID 31779273. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953105/.
↑  “A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma”. Blood 134 (2):  123–133. (July 2019). doi:10.1182/blood-2019-02-895193. PMC 6659612. PMID 30862646. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659612/.
↑  Martin, Thomas (December 7, 2015). “A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma”. ASH. 2021年10月10日閲覧。
↑  “Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM).”. Journal of Clinical Oncology 36 (15_suppl):  TPS8055. (2018-05-20). doi:10.1200/JCO.2018.36.15_suppl.TPS8055.
↑  “Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design”. Future Oncology 16 (2):  4347–4358. (January 2020). doi:10.2217/fon-2019-0431. PMID 31833394.
↑  “Isatuximab Orphan Drug Designations and Approvals”. U.S. Food and Drug Administration (FDA) (24 December 1999). 4 March 2020閲覧。
↑  “Drug Approval Package: Sarclisa”. U.S. Food and Drug Administration (FDA) (25 March 2020). 21 March 2021閲覧。
↑  Attal, Michel; Richardson, Paul G; Rajkumar, S Vincent; San-Miguel, Jesus; Beksac, Meral; Spicka, Ivan; Leleu, Xavier; Schjesvold, Fredrik et al. (2019). “Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study”. The Lancet 394 (10214):  2096–2107. doi:10.1016/s0140-6736(19)32556-5. ISSN 0140-6736. PMID 31735560.
↑  日経メディカル. “再発・難治性の多発性骨髄腫に抗CD38抗体イサツキシマブが承認”. 日経メディカル. 2021年10月11日閲覧。